First-line treatment of patients with HER2-positive metastatic gastric and gastroesophageal junction cancer.

Bosn J Basic Med Sci · 2022 · PMC9519153 · PMID 35460397

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Although a 3.3-month OS benefit was detected in the mFOLFOX+trastuzumab arm, it did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.